Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | TNKS | O95271 | 4/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.47 |
| ▸ | POLH | Q9Y253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.47 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.47 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312399 | 0.87 | KDM4E (0.62) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311824 | 0.84 | CSNK2A2 (0.53) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311467 | 0.84 | KDM4E (0.48) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL312246 | 0.84 | KDM4E (0.48) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311979 | 0.84 | CYP1B1 (0.48) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL1645853 | 0.83 | CYP1B1 (0.46) | KDM4ESMN1; SMN2CYP3A4HPGDTNKS | |
| SCHEMBL312584 | 0.81 | KDM4E (0.49) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311324 | 0.81 | NPC1 (0.60) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311321 | 0.81 | CSNK2A2 (0.67) | KDM4ESMN1; SMN2CYP3A4MAPTMAPK1 | |
| SCHEMBL311702 | 0.78 | ABCB1 (0.54) | KDM4ESMN1; SMN2CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | claimed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | KDM4E 3504/4885SMN1; SMN2 2736/4885CYP3A4 1730/4885 |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BCOR, BMI1, PHKB | KDM4E 186/4885SMN1; SMN2 2320/4885CYP3A4 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.